SomnoMed Limited (SOM) provides diagnostic and treatment solutions for Sleep-related Breathing Disorders including obstructive sleep apnea, snoring, and bruxism. The company began the 2022/23 financial year positively as the medical sector and broader dental community continued its global recovery from the COVID-19 pandemic. In this environment, SomnoMed was able to leverage the increasing awareness of sleep health and the importance of quality sleep for overall well-being. This focus on sleep health is expected to continue to drive demand for SomnoMed's products and services.